JP2009528987A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528987A5
JP2009528987A5 JP2008553534A JP2008553534A JP2009528987A5 JP 2009528987 A5 JP2009528987 A5 JP 2009528987A5 JP 2008553534 A JP2008553534 A JP 2008553534A JP 2008553534 A JP2008553534 A JP 2008553534A JP 2009528987 A5 JP2009528987 A5 JP 2009528987A5
Authority
JP
Japan
Prior art keywords
protein
yeast
influenza
antigen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008553534A
Other languages
English (en)
Japanese (ja)
Other versions
JP5198290B2 (ja
JP2009528987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/061572 external-priority patent/WO2007092792A2/en
Publication of JP2009528987A publication Critical patent/JP2009528987A/ja
Publication of JP2009528987A5 publication Critical patent/JP2009528987A5/ja
Application granted granted Critical
Publication of JP5198290B2 publication Critical patent/JP5198290B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008553534A 2006-02-02 2007-02-02 免疫反応を誘発する酵母ベースワクチン Expired - Fee Related JP5198290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
US60/765,025 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012260860A Division JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物

Publications (3)

Publication Number Publication Date
JP2009528987A JP2009528987A (ja) 2009-08-13
JP2009528987A5 true JP2009528987A5 (enExample) 2010-04-02
JP5198290B2 JP5198290B2 (ja) 2013-05-15

Family

ID=38345897

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008553534A Expired - Fee Related JP5198290B2 (ja) 2006-02-02 2007-02-02 免疫反応を誘発する酵母ベースワクチン
JP2012260860A Pending JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物
JP2014230982A Withdrawn JP2015038147A (ja) 2006-02-02 2014-11-13 免疫反応を誘発する酵母ベースワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012260860A Pending JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物
JP2014230982A Withdrawn JP2015038147A (ja) 2006-02-02 2014-11-13 免疫反応を誘発する酵母ベースワクチン

Country Status (14)

Country Link
US (2) US7736642B2 (enExample)
EP (2) EP1988919A4 (enExample)
JP (3) JP5198290B2 (enExample)
KR (2) KR20140029551A (enExample)
CN (2) CN101405026B (enExample)
AU (1) AU2007212076B2 (enExample)
BR (1) BRPI0706913A2 (enExample)
CA (1) CA2638815A1 (enExample)
IL (2) IL193196A (enExample)
IN (1) IN2014DN08830A (enExample)
MX (1) MX2008009929A (enExample)
SG (2) SG10201402236VA (enExample)
TW (2) TW201412329A (enExample)
WO (1) WO2007092792A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
CN101262883A (zh) * 2005-07-11 2008-09-10 环球免疫公司 引发针对靶向的疗法的逃逸突变体的免疫应答的组合物和方法
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
KR20140029551A (ko) * 2006-02-02 2014-03-10 글로브이뮨 면역 반응 유도를 위한 효모-기반 백신
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
WO2008054535A2 (en) * 2006-05-11 2008-05-08 Novavax, Inc. Novel influenza m2 vaccines
WO2008054540A2 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
JP5570819B2 (ja) * 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
MX2009010066A (es) * 2007-03-19 2009-10-12 Globeimmune Inc Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
WO2010036948A2 (en) * 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
US10383924B2 (en) 2009-04-17 2019-08-20 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
MX2011012312A (es) * 2009-05-18 2011-12-16 Panacea Biotec Ltd Vacuna universal para influenza basada en virus vaccinia ankara (mva) modificado recombinante.
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
US20120015346A1 (en) * 2010-07-08 2012-01-19 New York Medical College Influenza virus detection and diagnosis
SG10201709806VA (en) * 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US9173933B2 (en) * 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
AU2012212463B2 (en) * 2011-01-31 2016-07-07 Nanotherapeutics, Inc. Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
AU2012214394B2 (en) 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
JP6068368B2 (ja) * 2011-03-17 2017-01-25 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
WO2012162342A2 (en) * 2011-05-23 2012-11-29 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
CA2838950C (en) 2011-06-14 2020-10-27 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
AU2012273039B2 (en) * 2011-06-20 2016-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
PL2591798T3 (pl) * 2011-11-09 2015-04-30 Werner Lubitz Szczepionka do zastosowania w immunoterapii nowotworów
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
WO2014003853A1 (en) 2012-06-26 2014-01-03 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
EP2929351B1 (en) * 2012-12-10 2019-10-09 The University of Queensland Cell-free biofragment compositions and related systems, devices, and methods
KR20150128900A (ko) * 2013-03-15 2015-11-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-23을 갖는 백신
CA2907560C (en) 2013-03-19 2021-12-07 Timothy C. Rodell Yeast-based immunotherapy for chordoma
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
WO2015031778A2 (en) * 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
EP3092004A4 (en) * 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10166195B2 (en) 2014-03-05 2019-01-01 Orbis Health Solutions, Llc Vaccine delivery systems using yeast cell wall particles
WO2015157639A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
KR20180080178A (ko) * 2015-08-11 2018-07-11 오르비스 헬스 솔루션즈 엘엘씨 세균성 백신 및 바이러스성 백신 방법
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
AU2017281126A1 (en) 2016-03-24 2018-10-04 Nant Holdings Ip, Llc Sequence arrangements and sequences for neoepitope presentation
IL270132B2 (en) 2017-04-24 2024-12-01 Nantcell Inc Neoepitope vectors and methods for them
EP3730620A4 (en) * 2017-12-21 2022-01-05 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
DE102017012109A1 (de) 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN112543640B (zh) * 2018-05-15 2025-02-14 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
US12239699B2 (en) * 2018-09-11 2025-03-04 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
CA3138174A1 (en) * 2019-05-21 2020-11-26 David James O'hagan Yeast-based oral vaccination
CA3170538A1 (en) * 2020-02-11 2021-08-19 Cytonus Therapeutics, Inc. Rapid vaccine platform
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
WO2021211691A1 (en) 2020-04-14 2021-10-21 Immunitybio, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
WO1995018861A1 (en) * 1994-01-11 1995-07-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ES2295175T3 (es) * 2000-06-23 2008-04-16 Wyeth Holdings Corporation Ensamblaje de particulas similares al virus (vlp) de la gripe de tipo salvaje y quimericas.
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
AU2005248361B2 (en) * 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
CA2580537C (en) 2004-09-17 2015-04-21 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
KR20140029551A (ko) * 2006-02-02 2014-03-10 글로브이뮨 면역 반응 유도를 위한 효모-기반 백신

Similar Documents

Publication Publication Date Title
JP2009528987A5 (enExample)
Pardi et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
Freyn et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice
US11938221B2 (en) Multivalent nanoparticle-based vaccines
Wohlbold et al. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses
IL193196A (en) The total vaccine carried yeast and the protein of fusion of the influenza virus
Gerhard et al. Prospects for universal influenza virus vaccine
Song et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity
Branco et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever
Li et al. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates
Gao et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge
Kim et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection
Deliyannis et al. Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus
Lee et al. Mechanisms of cross-protection by influenza virus M2-based vaccines
Arunkumar et al. Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
Boshra et al. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR−/− mice upon lethal virus challenge
Du et al. Flu universal vaccines: new tricks on an old virus
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
Mbewana et al. Production of H5N1 influenza virus matrix protein 2 ectodomain protein bodies in tobacco plants and in insect cells as a candidate universal influenza vaccine
Choi et al. Chromatographically-purified capsid proteins of red-spotted grouper nervous necrosis virus expressed in Saccharomyces cerevisiae form virus-like particles
Bolduc et al. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses
Hoxie et al. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
Prokopenko et al. Truncation of NS1 protein enhances T Cell-mediated cross-protection of a live attenuated influenza vaccine virus expressing wild-type nucleoprotein